Organigram Global Inc. · TSX:OGI
Organigram Global — Investor Presentation (February 2025)
24 slides from Organigram Global's investor presentation, February 2025
Slide 1: Investor Presentation
INVESTOR PRESENTATION NASDAQ (OGI) TSX (OGI) 12 | 31 | 2024 1
Slide 2: Cautionary Statement
CAUTIONARY STATEMENT This document is current as of December 31, 2024, except where otherwise include factors and risks as disclosed in the Company’s most recent annual measures, including definitions, and a quantitative reconciliation to the most stated. The information contained in this presentati
Slide 3: Moncton's Flagship Facility
MONCTON’S FLAGSHIP FACILITY AN AWARD-WINNING LICENSED PRODUCER OF CANNABIS WITH A PRESENCE ACROSS CANADA AND A GROWING INTERNATIONAL FOOTPRINT Our Vision: To be a respected global leader in the emerging cannabis movement. Our Mission: To delight consumers with trusted brands that deliver innovative
Slide 4: Organigram Key Strengths
ORGANIGRAM KEY STRENGTHS The overall market leader in Canada with #1 positions in the fastest growing product categories of vapes and pre-rolls and top three positions in every major product category1 Five state-of-the-art specialized facilities including the largest indoor growing operation in Cana
Slide 5: #1 in Canada & Top 3 Market Share Across All Major Categories
#1 IN CANADA & TOP 3 MARKET SHARE ACROSS ALL MAJOR CATEGORIES RECREATIONAL FLOWER MILLED PRE-ROLLS INFUSED VAPES GUMMIES CONCENTRATES HASH MARKET (including milled) FLOWER (including IPRs) PRE-ROLLS (including hash) #1 #3 #1 #1 #2 #1 #3 #1 #1 Multiple Sources (Hifyre, Weedcrawler, p rovincia l bo ar
Slide 6: Coast-to-Coast Geographic Strength
COAST-TO-COAST GEOGRAPHIC STRENGTH Canada’s Largest Pure Play Cannabis Company By Market Share YT NT NU BC NL AB #1 SK / MB QC #1 ON #1 ATLANTIC #1 PE CANADA #1 #4 NB Moncton Facility Lac-Supérieur NS Winnipeg Facility Lac-Supérieur Facility Facility London & Aylmer Facilities (Motif) 6 Sou rce : Hi
Slide 7: Portfolio Anchored by Two Powerhouse Brands
PORTFOLIO ANCHORED BY TWO POWERHOUSE BRANDS LTM RETAIL BRAND LTM $ SHARE(1) DISTRIBUTION SALES(1) $230 4.2% 97% million $155 2.8% 90% million 1 .As of December 31 , 2024 – Multiple Sources 7 (Hifyre, Weedcrawler, p rovincia l bo ards, interna l mode lling).
Slide 8: Coverage Across All Segments and Categories
COVERAGE ACROSS ALL SEGMENTS AND CATEGORIES 8
Slide 9: Five State-of-the-Art Facilities Strategically Located Across the Country
FIVE STATE-OF-THE-ART FACILITIES STRATEGICALLY LOCATED ACROSS THE COUNTRY Winnipeg, MB Aylmer, ON London, ON Lac-Supérieur, QC Moncton, NB • Edibles facility with • Leverage Aylmer best-in-class • Centralized distribution hub to • Producing hang-dried, hand- • >85,000+ kg/year of low-cost, automated
Slide 10: Focused on Global Expansion
FOCUSED ON GLOBAL EXPANSION Organigram is deploying capital to establish a larger global presence while focusing on growing and diversifying its international revenue • Capital raised in Fiscal 2024: • $124.6 million follow-on investment from BAT to establish the $83.1 million Jupiter investment poo
Slide 11: Organigram's Global Footprint
ORGANIGRAM’S GLOBAL FOOTPRINT 11
Slide 12: BAT Investments in Organigram
BAT INVESTMENTS IN ORGANIGRAM Product Development Collaboration March 2021 - $221 million strategic investment from subsidiary of BAT for 19.9% equity interest1 in Organigram • Established the PDC with formation of a Center of Excellence ("CoE") at Moncton campus • Focused on developing the next ge
Slide 13: Product Development Collaboration
PRODUCT DEVELOPMENT COLLABORATION FASTTM Nanoemulsion technology for ingestible products is the first patent-pending innovation to be commercialized leveraging the output of the PDC Innovation Highlights • Organigram has unveiled the results of what is believed to be the largest pharmacokinetic (PK)
Slide 14: Jupiter Investment Pool
JUPITER INVESTMENT POOL Priority Investment Pillars The $83.1 million Jupiter investment pool targets Geographies investments in emerging cannabis opportunities • U.S. • Emerging global markets • All potential investments are made in alignment with Organigram’s strategic vision for the future, focus
Slide 15: Strategic Investments
STRATEGIC INVESTMENTS Geographies • $21 million investment into German cannabis leader Sanity Group to establish foothold in rapidly growing German market and expand export volume to Europe. • Expansion of Organigram’s previously announced supply agreement with Sanity Group • Opportunity to launch b
Slide 16: Quarterly Updates & Highlights
QUARTERLY UPDATES & HIGHLIGHTS Q1 F2025 16
Slide 17: Q1 F2025 Highlights
Q1 F2025 HIGHLIGHTS • Net revenue increased 17% to $42.7 million from $36.5 million in the same prior year period. • International sales increased by $2.3 million versus the same prior year period. • Adjusted gross margin1 increased to $14.3 million or 33%, from $11.2 million or 31% in the same prio
Slide 18: Quarterly Revenue & Adjusted Gross Margin
QUARTERLY REVENUE & ADJUSTED GROSS MARGIN1 37% 36% 33% 31% $69.9 31% $66.8 $63.6 $56.2 $56.3 $57.4 Long term trend of improving gross $48.4 $ millions margin and gross margin rate 20% 19% 1. Adjusted gross margin is a non-IFRS financial measure not defined by and does not have any standardized meani
Slide 19: Adjusted EBITDA
ADJUSTED EBITDA1 $5.9 $3.5 Significant year-over-year $ millions adjusted EBITDA growth $1.4 $0.1 $0.1 -$1.0 1. Adju sted EBITDA is a no n-IFRS Financial Measure not defined by a nd does n ot have any stand ardized meaning und er IFRS a nd might not be compara ble to similar fina ncia l measures dis
Slide 20: Strong Balance Sheet and Liquidity
STRONG BALANCE SHEET AND LIQUIDITY • On December 31, 2024, the Company had cash of $71.2 million (including restricted cash) • Pro-forma cash position of approximately $113 million, including restricted cash, upon the anticipated closing of the final tranche of the follow-on investment from BAT • N
Slide 21: Q1 F2025 Key Financial Metrics
Q1 F2025 KEY FINANCIAL METRICS KEY FINANCIAL METRICS Q1’25 Q1’24 % Change Gross revenue 66,806 56,270 19% Excise taxes (24,076) (19,815) 22% Net revenue 42,730 36,455 17% Cost of sales 28,615 26,944 6% Gross margin before fair value changes to biological assets & inventories sold 14,115 9,511 48% Re
Slide 22: Q1 F2025 Select Balance Sheet Metrics
Q1 F2025 SELECT BALANCE SHEET METRICS SELECT BALANCE SHEET METRICS 12-31-2024 09-30-2024 % Change Cash 44,298 106,745 (59)% Restricted cash 24,386 25,860 (6)% Short term investments 2,499 821 204% Biological assets & inventories 103,953 82,524 26% Other current assets 56,355 46,269 22% Accounts pay
Slide 23: Capital Structure
CAPITAL STRUCTURE CAPITAL STRUCTURE 12-31-2024 02-06-2025 Common shares issued and outstanding 126,157 126,217 Preferred shares1 8,463 8,463 Options 2,684 2,680 Warrants 4,451 4,451 Top-up rights 18,111 18,086 Restricted share units 3,695 3,634 Performance share units 1,828 1,824 Total fully dilut
Slide 24: A Canadian Cannabis Leader
A CANADIAN CANNABIS LEADER NASDAQ (OGI) TSX (OGI) 24
Organigram Global — Investor Presentation (February 2025) on 6ix